|20th May 2015
In the UK, the marketing of prescription medicine to health professionals and patients is carried out under strict regulatory oversight to protect and support high quality patient care. The ABPI Code of Practice for the Pharmaceutical Industry is administered by the Prescription Medicines Code of Practice Authority, and is a self-regulatory code that applies to the marketing of prescription medicines both to health professionals and the public as a whole.
When designing digital services and informational materials for prescription drugs or services, there are unique considerations that must be taken around how that information is accessed and used. In this blog, Senior Consultant Craig Moore, from the Blue Latitude Health Strategy team, discusses the application of the ABPI Code, including incorporating social media into digital patient services.
Do some market researchto understand the customer needs: would patients be interested in the social media functionality; would they use it? Rounds of user research and user testing would highlight if this was important or not.
At Blue Latitude Health, the aim is to solve problems for clients following a number of solution design methodologies.
Host a PMCPA (Prescription Medicines Code of Practice Authority)training session and take the opportunity to get feedback on early solution concepts. Understand where other companies have breached the code and where you may run the risk with your own solutions. The PMCPA’s view is absolute; any company working with or providing services for the Pharma Industry needs to know the code. (Blue Latitude Health’s staff have all completed the introductory PMCPA training session).
Get cross-functional teams around a meeting table to highlight social media in the organisation. The corporate communication team handles social throughout most organisations. Silos mean that the information is not always shared. The development of the website/app should not be the main focus; the main focus should be to capture any company-wide issues or concerns about using social, and highlight areas of the code that are designed to support this. Take any objections away and incorporate them into the business case for the solution.
Consider the level of patient access in the kind of website/app you want to develop. Patient access will raise some red flags, especially from the pharma-covigilance teams. The fear would be that an increased perception of patients discussing product-related issues would lead to an inundation of Adverse Events or Product Complaints (AE/PC).
Initiate some monitoring pilots related to the therapy area in general. This will help establish a reporting process; defining clear roles and responsibilities as well as outlining clear project plans, objectives, and exit strategies. Always follow the guidelines, and go beyond them.
For example, use what you report (or consider to be) an AE/PC as a metric to demonstrate that social listening will not create an undue burden on internal resources. Once the process is established, expand monitoring into competitor products – there is no need to report AE/PC for competitors – then, move on to company-owned products.
Look at the possibility of developing a solution for closed patient communities. The code explains how use of social media to discuss prescription medicines (for example, on Twitter) is seen as promotional. With closed patient communities, the challenge to the code/internal MLR compliance teams is to make sure to only allow access to prescribed patients. Canada, for example, uses product identification numbers and DIN to allow access to a patient programme or forum.
If you’d like to discuss digital solutions for patient communities or how the ABPI Code impacts digital services in more depth, we’d love to hear from you! Get in touch with us at firstname.lastname@example.org.
|25th April 2019
Patient advocate Trishna Bharadia explains why shared decision making is crucial for ensuring multiple sclerosis patients feel heard and empowered
|18th April 2019
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients.
|10th April 2019
A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team and reveals the innovative engineering behind the pill.